1.1300
23-May-25 13:45:00
15 minutes delayed
Stocks
+0.0100
+0.89%
Today's range
1.0900 - 1.1392
ISIN
N/A
Source
NASDAQ
Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors
18 Sep 2024 05:30:00 By Nasdaq GlobeNewswire